Regeneron Pharmaceuticals Inc Roundtable Lynozyfic Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Simon Baker - Redburn Partners LLP - Analyst : Just wanted to dig a little bit deeper into early feedback on Lynozyfic use. If you could give us some idea of the characteristics of patients and prescribers at this stage, particularly the split between community and academic center prescription, that would be really helpful.

Question: Mohit Bansal - Wells Fargo Securities LLC - Analyst : And I think my question is also a little bit big picture. So oftentimes, we have seen in competitive markets. I mean, the drug could be better, but at the same time, I think the development strategy could be more important. And it does seem like that there is a lot of emphasis on early-stage myeloma here. Can you talk a little bit about the strategy there? I mean how do you think you are differentiating the key parts of differentiation versus a competitor from J&J and all other bispecifics, which are also trying to do the same. But how would you think that you could be differentiated on the development side of things?